R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

This early-phase study tests combining R-5780-01 — a new experimental compound — with an anti-PD-1 immune checkpoint inhibitor (a type of immunotherapy) in patients with advanced solid tumors that have stopped responding to standard treatments. **You may be eligible if...** - You have an advanced solid tumor (such as lung, kidney, colorectal, or other cancer) - Your cancer has progressed despite standard treatments - You are at least 18 years old with adequate organ function - You are willing to undergo tumor biopsies as required by the protocol **You may NOT be eligible if...** - You have active, uncontrolled brain metastases - You have a serious autoimmune disease that could be worsened by immunotherapy - You have had severe side effects from prior anti-PD-1 therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.